News and Events

First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma

On February 16, 2024, the Food and Drug Administration approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes (TILs), for some people with advanced melanoma. TIL therapy was pioneered in the 1980s by Steven A. Rosenberg, M.D., Chief of the Surgery Branch, and the final approval of this treatment has taken years of clinical trial research and ongoing partnerships among multiple institutions.

Read More

New Milestones publication now available

Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestones, features 10 of our top scientific advances from the past year. These discoveries fall everywhere on the spectrum from basic science to clinical research, ranging from a change in our understanding of how cells replicate and divide to the first FDA-approved treatment for a rare cancer based on the results of an NCI trial. Our researchers have developed a novel drug delivery system inspired by bacterial spores, identified prognostic gene signatures for patients with different cancers and gathered data over 30 years to show that an immunotherapy essentially cures a rare precancerous disease.

Read More

Steven Rosenberg receives AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) has awarded Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, the AACR Award for Lifetime Achievement in Cancer Research. He is being recognized for his paramount contributions to cancer research and patient care, most notably his pioneering research in establishing cancer immunotherapy as a major treatment strategy for many cancer types. He will receive the award at the 2024 AACR Annual Meeting. 

Read More